Sep 23, 2016 a clinical trial comparing efficacy and safety of dabigatran etexilate with warfarin in patients with cerebral venous and dural sinus thrombosis respect cvt the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Rivaroxaban versus warfarin and dabigatran in atrial. For the dabigatran 110 mg vs warfarin comparison, the model is stratified by age, nonelderly vs elderly dabigatran 150 mg vs warfarin comparison, an unstratified model is used, elderly patients outside the usa are excluded. Dental extractions on direct oral anticoagulants vs. To the editor in a recent issue of jama internal medicine, graham et al1 reported that rivaroxaban use increased risks of major bleeding with nonsignificant reduction in thromboembolic stroke and increased mortality compared with dabigatran in elderly medicare beneficiaries newly treated with. Dabigatran versus warfarin for atrial fibrillation in. Dabigatran versus warfarin for stroke prevention in patients. Compare coumadin vs pradaxa headtohead with other drugs for uses, ratings, cost, side effects, interactions and more. Dabigatran vs rivaroxaban for nonvalvular atrial fibrillation. A prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin.
A clinical trial comparing efficacy and safety of dabigatran. These recommendations refer to transitioning patients who are taking dabigatran on a long term basis and are switching to warfarin instead clcr 50 mlmin. Safety and effectiveness of dabigatran and other direct. In comparison to doac users, patients on warfarin were more often male, had more teeth extracted, and had higher rates of primary closure ie, wound edges able to be brought together. Background warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dec 17, 2009 dabigatran may prove to be an alternative to warfarin in patients with atrial fibrillation.
Safety and efficacy of dabigatran etexilate vs dose. Ly trial comparing dabigatran and warfarin, dabigatran 150 mg reduced the risk of stroke or systemic embolism with a similar risk of major bleeding. With the recent introduction of several novel oral anticoagulants noacs on the u. For the dabigatran 110 mg vs warfarin comparison, the model is stratified by age, nonelderly vs elderly 50 mlmin. Several cases have been identified where dabigatran and enoxaparin were administered concurrently, placing patients at. Advise patient to notify health care professional if pregnancy is planned or sus. The decision between initiating dabigatran or warfarin is influenced by indication and the patients characteristics, e. An occurrence of rebleeding from the venipuncture site was less common in dabigatran. Dabigatran with or without concomitant aspirin compared with. Dabigatran etexilate is rapidly absorbed after oral administration and is converted to dabigatran.
The study objective was to evaluate the safety and effectiveness of dabigatran and other direct oral anticoagulants doacs compared with warfarin among patients with nonvalvular atrial fibrillation using a prospective monitoring program. Dabigatran may prove to be an alternative to warfarin in patients with atrial fibrillation. Findings in this exploratory randomized, openlabel clinical trial of 120 patients with cerebral venous thrombosis, no recurrent venous thrombotic events were observed in patients randomized to either the dabigatran or warfarin treatment group. A randomized controlled trial of dabigatran versus. Target specific oral anticoagulants dabigatran pradaxa, rivaroxaban xarelto, and apixaban eliquis september 20 vha pharmacy benefits management services, medical advisory panel and visn pharmacist executives objective. Efficacy of dabigatran versus warfarin in patients with. In warfarin treated patients, the time in therapeutic range was 71. Dabigatran compared with rivaroxaban vs warfarin jama. Atrial fibrillation af increases the risk of having stroke as high as five fold. Pradaxa dabigatran is an effective oral medicine for preventing and treating blood clots, but it can increase the risk of bleeding especially in older people and those with kidney problems. As compared with warfarin, which is taken once daily, dabigatran needs to be taken twice daily. There were no significant differences between the two treatment groups in the frequency of any adverse events except for dyspepsia 2. Effectiveness and safety of oral anticoagulants among.
Apixaban eliquis is a new direct oral factor xa inhibitor. Advantages and disadvantages of novel oral anticoagulants. The study was conducted in 44 countries and included 18 1 patients. Dual antithrombotic therapy with dabigatran after pci in. Your body produces a chemical called thrombin that is needed in order to form a blood clot. Dabigatran admin istered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but. Dabigatran versus warfarin in the treatment of acute. The advantages of dabigatran over warfarin are as follows.
Cox regression analysis for interaction showed that treatment efficacy dabigatran etexilate vs warfarin was not significantly affected by the presence or absence of thrombophilia table. Dabigatran as oral predictable anticoagulant drug, have been approved by food and drug association fda for stroke prevention and systemic embolism in. Dec, 2010 pdf dabigatran versus warfarin in patients with atrial fibrillation. Background the direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism. Effect of pgp inducers and inhibitors on dabigatran.
Dabigatran is a new medication that works differently than warfarin. Pdf dabigatran versus warfarin in the treatment of acute venous. Safety and efficacy of dabigatran vs warfarin after cvt jama. Apixaban vs warfarin in patients with atrial fibrillation 1 apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation. Pdf the direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients. The requirements are different to when starting warfarin or switching between warfarin and enoxaparin. May 27, 2016 abstract purpose to evaluate effectiveness and safety of rivaroxaban versus warfarin or dabigatran etexilate in a prospective cohort of routine care non. The predictable pharmacokinetic profile and minimal food and drug interactions of dabigatran allow for a fixed. We defined lvh by electrocardiography ecg and included patients with af on the ecg tracing at entry. Recently, the fda food and drug administration approved a new blood thinner medication called dabigatran pradaxa. Methods a retrospective observational study of nonvalvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin from january 1, 20, to september 30, 2015, was conducted pooling centers for medicare and medicaid services medicare data and 4 us commercial claims databases. Nov 01, 2007 this is the first evaluation of dabigatran, an oral direct thrombin inhibitor, in patients with atrial fibrillation af.
Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Abstract dabigatran etexilate dabigatran is a novel, oral, reversible, direct thrombin inhibitor that exhibits several advantages over warfarin for therapeutic anticoagulation. Methods and results 17 studies were included after a thorough search in pubmed for studies reporting comparative effectiveness and safety of r vs. Comparing dabigatran, apixaban, and rivaroxaban in the. Dabigatran helps to prevent blood clots by blocking the effect of thrombin. Guidelines for management of bleeding with dabigatran or rivaroxaban.
Dabigatran and warfarin have many different features. Direct comparison of dabigatran, rivaroxaban, and apixaban. Dabigatran etexilate an overview sciencedirect topics. Of these, 37,174 patients were instituted on warfarin, 6574 on dabigatran, 8323 on rivaroxaban and 12,311 on apixaban. Pradaxa dabigatran etexilate mesylate capsules for oral use. Hrs and wald cis from cox proportionalhazard model. Abstract purpose to evaluate effectiveness and safety of rivaroxaban versus warfarin or dabigatran etexilate in a prospective cohort of routine care non. Guidelines for management of bleeding with dabigatran or. Warfarin medication is best suited as a blood thinner for those who are at risk of blood clot formation in the future. Efficacy and safety of dabigatran versus warfarin from. Pdf dabigatran versus warfarin in the treatment of acute. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation.
Directacting oral anticoagulants doacs, dabigatran, rivaroxaban, apixaban. Prior to rely, warfarin was the primary anticoagulant used in the prevention of thromboembolic stroke among patients with atrial fibrillation af. Dabigatran is a fixeddose, oral direct thrombin inhibitor with similar or reduced rates of ischemic stroke and intracranial hemorrhage in patients with af compared with those of warfarin. Effectiveness and safety of apixaban, dabigatran, and. Pdf dabigatran versus warfarin in patients with atrial.
Dabigatran is a new oral direct thrombin inhibitor. Dabigatran vs warfarin for radiofrequency catheter. Tee was performed before cardioversion more often in patients assigned to dabigatran than in those receiving study warfarin 25. Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus doseadjusted warfarin in patients with cerebral venous thrombosis. The comparative effectiveness and safety of dabigatran versus warfarin appear to be somewhat attenuated in routine clinical practice. A complete list of investigators in the randomized evaluation of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin in patients with nonvalvular atrial fibrillation. Warfarin has been used for many years to decrease the tendency of thrombosis and secondary prophylaxis. It is an oral prodrug that is rapidly converted by a serum esterase to dabigatran, a potent, direct, competitive thrombin inhibitor. Warfarin reduces the risk for ischemic stroke in patients with atrial fibrillation af but increases the risk for hemorrhage. There was a lot of interest in the introduction of noacs for the prevention and treatment of thrombosis.
I just heard about a new drug i can take instead of warfarin. Cox regression analysis for interaction showed that treatment efficacy dabigatran etexilate vs warfarin was not significantly affected by the presence or absence of thrombophilia table 4. The safe and effective use of dabigatran and warfarin in. Dabigatran versus warfarin for atrial fibrillation.
Connolly, published in the new england journal of medicine, 2009. Pdf dabigatran compared with warfarin for stroke prevention in. Dabigatran was associated with similar risk of stroke or systemic embolism compared with warfarin hr 0. Effectiveness and safety of dabigatran, rivaroxaban, and. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but. Warfarin coumadin or dabigatran pradaxa how do these blood thinners compare. The original version pdf is appended to this article as a supplement background. Comparison of dabigatran and warfarin used in patients with non. Its halflife is about 8 hours after a single dose and 1417 hours after multiple doses. It requires regular blood tests and youll need to eat, exercise, and take your medicines consistently. The aim of this study was to evaluate dabigatran dual therapy versus warfarin triple therapy in patients with or without diabetes mellitus in the redual pci randomized evaluation of. Dabigatran versus warfarin in patients with atrial.
Warfarin coumadin or dabigatran pradaxa how do these. Dabigatran versus warfarin in patients with atrial fibrillation nejm. In the rely trial, patients receiving warfarin or dabigatran had a similar rate of discontinuation of study medication 17% vs 21%. This is a posthoc analysis of the randomized evaluation of longterm anticoagulation therapy rely study. There appears to be a doserelated tradeoff between increased efficacy and increased bleeding complications. Background edoxaban is a direct oral factor xa inhibitor with proven antithrombotic effects. Dabigatran etexilate pradaxa is a direct thrombin inhibitor administered once or twice daily depending on indication. Question is dabigatran etexilate or doseadjusted warfarin efficacious and safe to use in preventing the recurrence of venous thrombotic events among patients with cerebral venous thrombosis findings in this exploratory randomized, openlabel clinical trial of 120 patients with cerebral venous thrombosis, no recurrent venous thrombotic events were observed in patients. These data were presented as an oral abstract april 3, 2016 at the american college of cardiology scientific sessions, chicago il. For the treatment of acute venous thromboembolism, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfarin, and. Objective to evaluate the effectiveness and safety of rivaroxaban in realworld practice compared with dabigatran r vs. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation.
Coumadin warfarin is a cheap and effective medicine that prevents new blood clots. The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism. Dabigatran versus warfarin in the treatment of acute venous. The rate of hemorrhagic stroke was significantly lower in the group taking 110 or 150 mg of dabigatran vs. Dabigatran etexilate is a prodrug of dabigatran, a specific, competitive, and reversible inhibitor of thrombin. The rivaroxabandabigatran comparison had 15,800 patients in each group, and the apixabandabigatran and apixabanrivaroxaban comparisons had about 6500 patients in each group. The study included 64,382 patients corresponding to 81,176 treatment years.
The longterm efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrilla. The vitamin k antagonist, warfarin, has a long halflife and narrow therapeutic range necessitating regular monitoring and is a common cause of iatrogenic hospital admission. Most patients on dabigatran take 150 mg two times a day. Bleeding in the elderly and renal impaired patients 5 dabigatran related deaths in japan 4. This commentary refers to dabigatran versus warfarin in patients with atrial fibrillation, by s. No significant differences were found in the risk of ischemic stroke or hemorrhagic stroke, but the risk of hemorrhagic stroke was numerically lower in dabigatran patients hr 0.
Results for the primary outcomes comparing the lower renal doses of rivaroxaban 15 mg once daily vs dabigatran 75 mg twice daily showed a similar pattern etable 3 in the supplement. Efficacy of dabigatran versus warfarin in patients with acute. Warfarin for stroke prevention in nonvalvular atrial fibrillation priya patel, jheel pandya. However, the 110 mg dabigatran associated lower incidence of bleeding compare with warfarin. Pradaxa dabigatran etexilate mesylate capsules is a prescription blood thinner medicine that lowers the chance of blood clots forming in your body. Efficacy and safety of dabigatran versus warfarin from the re. Using propensityscore matching, demographically and clinically similar cohorts were created for each twoway comparison. Costeffectiveness of dabigatran compared with warfarin. Dabigatran versus warfarin in patients with atrial fibrillation. For the dabigatran 110 mg vs warfarin comparison, the model is stratified by age, nonelderly vs elderly warfarin, highdose dabigatran reduces stroke risk without increasing the risk of major bleeding among patients with atrial fibrillation.
Dabigatran 150 mg twice daily has been associated with lower rates of stroke than warfarin in trials of atrial fibrillation, but largescale evaluations in clinical practice are limited. Uninterrupted dabigatran versus warfarin for ablation in atrial. Dabigatran was switched to warfarin before the ablation because of dyspepsia in three patients. Patients n 502 were randomized to receive blinded doses of 50, 150, or 300mg dabigatran twice daily alone or combined with 81 or 325mg aspirin or openlabel warfarin. Connolly sj, ezekowitz md, yusuf s, eikelboom j, oldgren j, parekh a, pogue j, reilly pa, themeles e, varrone j, wang s, alings m, xavier d, zhu j, diaz r, lewis bs, darius h, diener hc, joyner cd, wallentin l. Dabigatran versus warfarin for atrial fibrillation annals. For secondary outcomes, there was a statistically significant increase in all hospitalized extracranial bleeding events with rivaroxaban and no difference. Efficacy and safety of dabigatran versus warfarin from the.
264 415 1427 271 905 685 168 1375 379 636 1150 698 371 846 1360 574 1177 300 1027 1157 855 805 390 310 1433 714 889 144 523 56 425 237 244 134 477 394 312 61 421 547 888 1244